Companies Dominating the Albumin Landscape
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The worldwide market is vigorously gaining increased exposure with the presence of leading organizations, including Takeda, Grifols, and CSL Behring, collectively controlling the market with a combined share of 46%. These players have readily implemented strategies, such as biopharmaceutical partnerships and collaboration, research and development activities for recombinant albumin, plasma self-sufficiency, and market penetration. For instance, Seqirus and Baxter successfully partnered with each other to supply albumin for mRNA vaccine stabilizers. Likewise, LFB Group and Takeda initiated an investment of more than USD 520 million for yeast-based alternatives to albumin, thereby creating a positive influence on the overall market.
Here is a list of key players operating in the global market:
|
Company Name (Country) |
Industry Focus |
Market Share (2024) |
|---|---|---|
|
CSL Behring (U.S.) |
Plasma-derived albumin, recombinant albumin for therapeutics & biopharma |
18.2% |
|
Grifols (Spain) |
Human serum albumin (HSA) for critical care & diagnostics |
15.3% |
|
Takeda Pharmaceuticals (U.S.) |
Plasma fractionation, albumin for burns & liver disease |
12.4% |
|
Octapharma (Switzerland) |
Liquid & lyophilized albumin, focus on ICU and emergency medicine |
10.1% |
|
Baxter International (U.S.) |
Albumin solutions for surgeries & hypoalbuminemia |
8.9% |
|
Kedrion Biopharma (Italy) |
Plasma-derived albumin, specialized in pediatric and geriatric applications |
xx% |
|
Biotest (Germany) |
HSA for biopharmaceutical excipients and clinical use |
xx% |
|
LFB Group (France) |
Recombinant albumin for vaccines & monoclonal antibodies |
xx% |
|
Sanquin (Netherlands) |
Non-profit plasma collector, supplies albumin to EU hospitals |
xx% |
|
Bio Products Laboratory (UK) |
Albumin for rare diseases and trauma care |
xx% |
|
SK Plasma (South Korea) |
Emerging leader in Asian plasma-derived albumin |
xx% |
|
Biological E. Ltd. (India) |
Low-cost albumin for emerging markets, focus on India & Southeast Asia |
xx% |
|
Serum Institute of India |
Affordable albumin for LMICs, partnerships with WHO |
xx% |
|
Protheragen (Malaysia) |
Contract manufacturing of albumin for biopharma |
xx% |
|
Seqirus (Australia) |
Albumin as stabilizer for vaccines (e.g., influenza) |
xx% |
Below are the areas covered for each company under the top 15 global manufacturers:
